*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
First Half of FY 2023
Financial Results Briefing
Friday, November 25, 2022
Linical Co.,Ltd.
TSE Prime 2183
Contents
1. Company Overview
P. 2 - 4
2. Financial Results for the Six Months
Ended September 30, 2022
P. 5 - 13
3. Growth Strategy
P. 14 - 39
1. Company Overview
Global CRO from Japan
Locations of Overseas Bases
Sweden
Portugal
Germany
Spain Czech Republic
Poland France
Hungary Romania
UK Netherlands
Italy
October 2022
Establishment of an
Italian subsidiary
Beijing
Canada
Korea
Tokyo
San Diego
New York
Shanghai
Osaka
India
(Linical Headquarters)
Florida
Taiwan
Mexico
Philippines
Singapore
Brazil
Indonesia
Australia
Chile
Argentina
Red: Headquarters Orange: Branch Pink: Subsidiary Blue: Subsidiary Green: CRA Employment ash: Under consideration as base
Linical aims to be a global CRO originating in Japan and undertakes to new drug development as a drug development professional
We have advanced overseas positively since the founding of the company and currently operate in 18 countries and regions
3
The Three Businesses of Linical
We specialize in clinical development and cover the entire process from the innovative drug development stage through to the new drug development and approval stages.
Innovative drug
development
process
Basic research
Application to
Clinical trials
Post-marketing
(2 to 3 years) to
New drug
surveillance and
start a new
phases I to III
non-clinical trials
application
clinical trials
drug trial
(3 to 7 years)
(3 to 5 years)
(4 to 10 years)
The three
businesses of
Linical
CRO business
Contract Medical Affairs
From 2005
From 2011
Innovative Drug
● Market analysis ● Handling of pharmaceutical affairs
Development Business● Development strategy planning ● Partnering support
From 2016
We have developed three businesses centered on CRO business.
• Contract Medical Affairs business:
We support post-marketing clinical research and marketing activities
Innovative Drug Development Business :We provide consulting services that give total support for a wide range of pharmaceutical development activities including market analysis, the formulation of pharmaceutical affairs and development strategies, the selection of marketing partners, and the conclusion of contracts.
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Linical Co. Ltd. published this content on 27 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:19:48 UTC.
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.